Bio Protocol has just officially announced the V2 upgrade, and the new points system BioXP is officially launched. I have been following this project for a while, and I can now basically qualify it: a heavy asset player in DeSci, with strong research implementation capabilities, and top-tier financing and partners. 1. What is BioAgent? In one sentence: an on-chain AI scientist that can earn points, subscribe, and participate in research financing. More importantly, each Agent's token has a trading pool, and the trading fees directly support the experiments themselves, truly achieving research while trading. 2. How to participate? Starting from July 30, you can stake BIO or ecological assets to earn BioXP points. BioXP = whitelist certificate for new projects. 👉 The earlier you stake, the more BioXP points you earn. 👉 Each subscription is completely on-chain, and once it's gone, it's gone. 3. Why am I participating? - Bio Protocol has facilitated over $50 million in research financing, with partner institutions including VitaDAO, Harvard Med, Pfizer Ventures, and more. - The project mechanism is clear, with all financing going into LP, zero market value management risk. - The Agent itself is a growing AI module, with data, funds, and research activities all on-chain. To be honest, this round is not for the sake of gaining attention, but to secure a position. - Aubrai is the first, and there will be more BioAgents and IP assets launched later. - What I’m earning are points, what I’m getting is subscription rights, and what’s bound is the entire on-chain research mainline. Now is a low traffic + high density phase, suitable for heavy investment. Once it really explodes, mainstream influencers won’t slowly explain the mechanism anymore; they will just post pictures and shout about the price increase. Staking entry: BioXP mechanism: I have already started accumulating BioXP.